Is ALKS or IMVT more profitable?

ALKS runs the higher net margin — ALKS at 3.97% versus IMVT at -7585.86%.

How have ALKS and IMVT total returns compared?

Over the past 5 years, ALKS delivered 6.73% and IMVT delivered 29.93% annualized total return. Past performance doesn't predict future results.

Alkermes plc (ALKS) vs Immunovant, Inc. (IMVT)

A side-by-side comparison of Alkermes plc and Immunovant, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ALKS

Alkermes plc

$6.95B

$41.40HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT

IMVT

Immunovant, Inc.

$6.62B

$32.07HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT

Total return — ALKS vs IMVT

growth of $100 · dividends reinvested · last 7y

ALKS +91.5% (+9.7%/yr)IMVT +234.2% (+18.8%/yr)IMVT compounded faster over this window

ALKS IMVT

ALKS vs IMVT: by the numbers

•ALKS is the larger company ($6.95B vs $6.62B market cap).
•ALKS is profitable (3.97% net margin) while IMVT runs a net loss (-7585.86%).

Metrics side by side

Valuation

Metric	ALKS	IMVT
P/E ratio	108.09	N/A
P/S ratio	4.16	932.95
P/B ratio	3.84	9.00
EV / EBITDA	44.75	N/A
FCF yield	3.19%	N/A

Profitability

Metric	ALKS	IMVT
Gross margin	84.56%	0.00%
Operating margin	17.21%	0.00%
Net margin	3.97%	-7585.86%
ROE	3.66%	-73.19%
ROIC	2.12%	-76.00%

Growth (annualized)

Metric	ALKS	IMVT
Revenue CAGR (5Y)	8.68%	N/A
FCF CAGR (5Y)	20.00%	N/A
Total return CAGR (5Y)	6.73%	29.93%

Frequently asked

Is ALKS or IMVT more profitable?: ALKS runs the higher net margin — ALKS at 3.97% versus IMVT at -7585.86%.
How have ALKS and IMVT total returns compared?: Over the past 5 years, ALKS delivered 6.73% and IMVT delivered 29.93% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ALKS analysis Full IMVT analysis Interactive comparison tool

Dig into the metrics

Alkermes P/E ratio Alkermes ROE Immunovant ROE Alkermes operating margin Immunovant operating margin Alkermes revenue growth Immunovant revenue growth Alkermes free cash flow Immunovant free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.